

Curriculum Vitae Europass

INFORMATII PERSONALE



Nume/Prenume	JINGA VIOREL
Adresa	
Fax	+40214104133
E-mail	vioreljinga@yahoo.com
Nationalitate	Română
Data nasterii	
Sex	Masculin

EXPERIENTA PROFESIONALA

1. Medic primar urolog, doctor in stiinte medicale, Clinica Urologie – Spitalul Clinic „Prof. Dr. Th. Burghele”, Bucuresti, Romania
2. Profesor universitar, Clinica de Urologie, Spitalul Clinic „Prof. Dr. Th. Burghele”, Universitatea de Medicina si Farmacie „Carol Davila”, Bucuresti, Romania
3. Director Medical Spitalul Clinic „Prof. Dr. Th. Burghele”, Bucuresti
4. Prodecan al Facultatii de Medicina – Universitatea de Medicina si Farmacie „Carol Davila”, Bucuresti
5. Prorector al Universitatii de Medicina si Farmacie „Carol Davila” Bucuresti
6. Rector al Universitatii de Medicina si Farmacie „Carol Davila” Bucuresti

EXPERIENTA PROFESIONALA

Perioada	1998 – prezent
Functia sau postul ocupat	Medic primar specialitatea urologie, confirmat prin Ordinul M.S.nr. 694/1998
Numele si adresa angajatorului	Clinica Urologie, Spitalul Clinic „Prof. Dr. Th. Burghele”, Sos. Panduri, Nr.20, cod 021782, Sector 5, București, România
Tipul activitatii sau sectorul de activitate	Sanatate, cercetare clinica, invatamant medical

Perioada	Octombrie 2013 - prezent
Funcția sau postul ocupat	Profesor Universitar (poziția 1) disciplină Urologie, Facultatea de Medicină, Universitatea de Medicină și Farmacie „Carol Davila” București
Principalele activități și responsabilități	• cursuri și lucrări practice în cadrul modului de urologie, pentru studenții Universității de Medicină și Farmacie Carol Davila, București, • cursuri cu tematică de urologie medicilor rezidenți care au efectuat module de urologie în Spitalul Clinic „Prof. Dr. Th. Burghel”, București, România • cercetare clinică • publicarea articolelor științifice
Numele și adresa angajatorului	Clinica de Urologie, Spitalul Clinic „Prof. Dr. Th. Burghel”, Universitatea de Medicină și Farmacie, Carol Davila, București, România
Tipul activității sau sectorul de activitate	Invatamant medical, cercetare clinică
Perioada	Septembrie 2009 – Aprilie 2016
Funcția sau postul ocupat	Director Medical
Principalele activități și responsabilități	Coordonarea activității medicale din cadrul spitalului
Numele și adresa angajatorului	Clinica Urologie, Spitalul Clinic „Prof. Dr. Th. Burghel”, Sos. Panduri, Nr.20, cod 021782, Sector 5, București, România
Tipul activității sau sectorul de activitate	Sanatate
Perioada	Octombrie 2007 – Septembrie 2009
Funcția sau postul ocupat	Sef de secție
Principalele activități și responsabilități	Coordonarea activității din cadrul secției
Numele și adresa angajatorului	Secția Urologie III, Spitalul Clinic „Prof. Dr. Th. Burghel”, Sos. Panduri, Nr.20, cod 021782, Sector 5, București, România
Tipul activității sau sectorul de activitate	Sanatate
Perioada	Iunie 2012 – Martie 2016
Funcția sau postul ocupat	Prodecan al Facultății de Medicină
Principalele activități și responsabilități	Management universitar
Numele și adresa angajatorului	Universitatea de Medicină și Farmacie „Carol Davila” București
Perioada	Martie 2016 - Prezent
Funcția sau postul ocupat	Prorector al U.M.F „Carol Davila”
Principalele activități și responsabilități	Management universitar
Numele și adresa angajatorului	Universitatea de Medicină și Farmacie “Carol Davila”, București
Perioada	Martie 2020 - Prezent

Functia sau postul ocupat	Rector al U.M.F „Carol Davila”
Principalele activitati si responsabilitati	Management universitar
Numele si adresa angajatorului	Universitatea de Medicina si Farmacie „Carol Davila”

EDUCATIE SI FORMARE

Perioada	1982-1988
Calificarea / diploma obtinuta	Medic, Diploma nr. 229 / 27.12.1988
Numele si tipul institutiei de invatamint / furnizorului de formare	Student al Facultatii de Medicină Generală, Universitatea de Medicina si Farmacie Dr. Carol Davila, Bucuresti
Nivelul de clasificare a formei de invatamint / formare	Invatamant superior medical de lunga durata
Perioada	1990-1994
Calificarea / diploma obtinuta	Medic specialist în specialitatea urologie, confirmat prin Ordinul M.S.nr. 240/1994
Numele si tipul institutiei de invatamint / furnizorului de formare	Urmarea stagiului de pregatire in specialitatea urologie in Clinica Urologie – Spitalul Clinic „Prof. Dr. Th. Burghel”, Bucuresti, Romania
Nivelul de clasificare a formei de invatamint / formare	Invatamant postuniversitar, secundariat
Perioada	1994-1998
Calificarea / diploma obtinuta	Medic primar specialitatea urologie, confirmat prin Ordinul M.S. nr. 694/1998
Numele si tipul institutiei de invatamint / furnizorului de formare	Clinica Urologie – Spitalul Clinic „Prof. Dr. Th. Burghel”, Bucuresti, Romania
Nivelul de clasificare a formei de invatamint / formare	Invatamant postuniversitar
Perioada	1997-2000
Calificarea / diploma obtinuta	Doctor în medicină, specialitatea urologie; Diploma 979 / 15 XII 2000
Numele si tipul institutiei de invatamint / furnizorului de formare	Prin concurs doctorand în specialitatea urologie Titlul tezei “Aportul ecografiei Doppler in diagnosticul tumorilor renale” Conducător științific: Prof. Dr. Eugen Popescu Universitatea de Medicină și Farmacie Carol Davila, București,
Nivelul de clasificare a formei de invatamint / formare	Doctorat

Perioada 1993-1996
 Calificarea / diploma obtinuta Competenta in ecografie generala, certificat nr. 2707 / 05.06.1998
 Numele si tipul institutiei de invatamint / furnizorului de formare Ecografie generala
 Nivelul de clasificare a formei de invatamint / formare Competenta/Atestat de studii complementare

Perioada 1999-2000 (2 semestre)
 Calificarea / diploma obtinuta diploma nr. 285 / 18.07.2001
 Numele si tipul institutiei de invatamint / furnizorului de formare Studii postuniversitare de specializare in domeniul "Utilizarea Izotopilor radioactivi", organizat de Universitatea din Bucuresti-Facultatea de Fizica.
 Nivelul de clasificare a formei de invatamint / formare Studii postuniversitare

Perioada 2004
 Calificarea / diploma obtinuta Competenta/ atestatul in « Managementul Serviciilor de Sanatate » ; certificat seria C /nr. 010887/2 iunie 2004
 Numele si tipul institutiei de invatamint / furnizorului de formare Pregatire in vederea obtinerii competentei (atestatului) in « Managementul Serviciilor de Sanatate »
 Nivelul de clasificare a formei de invatamint / formare Competenta/Atestat de studii complementare

APTITUDINI SI COMPETENTE PERSONALE

Limba materna romana

Limbi straine cunoscute

Autoevaluare
 Nivel european ^(*)

Intelegere		Vorbire		Scriere
Ascultare	Citire	Participare la conversatie	Discurs oral	Exprimare scrisa

Limba engleza

C1	C1	C1	C1	C1
----	----	----	----	----

^(*) Cadrului european de referință pentru limbi straine

COMPETENTE SI ABILITATI SOCIALE

Bune capacitati de comunicare si negociere
 Spirit de echipa, Capacitate de adaptare
 Atitudine pozitivă, Entuziasm, Flexibilitate, Dinamism
 Abilități oratorice bune
 Atitudine orientata catre rezolvarea problemelor

COMPETENTE SI ABILITATI ORGANIZATORICE

Bună capacitate organizatorică – experiență acumulată ca și șef de disciplină, șef de clinică universitară, șef de secție clinică

Abilitati de leadership – Prodecan al Facultății de Medicină din cadrul U.M.F ”Carol Davila”, Prorector al U.M.F ”Carol Davila”

Abilități manageriale și experiență acumulată în managementul proiectelor de cercetare – director/responsabil în peste 20 de proiecte de cercetare naționale și internaționale

ALTE COMPETENTE SI APTITUDINI

AFILIERE LA SOCIETATI STIINTIFICE SI PROFESIONALE NATIONALE SI INTERNATIONALE:

I. Membru în societăți științifice naționale:

1. Asociația Română de Urologie

II. Membru în societăți științifice internaționale:

1. Societatea Medicală Balcanică
2. Societatea Europeană de Ultrasonografie
3. Asociația Europeană de Urologie (EAU)
4. Societatea Internațională de Urologie (SIU)
5. Asociația Americană de Urologie (AUA)

PERMIS DE CONDUCERE

Categoria B

ACTIVITATEA PROFESIONALA, DIDACTICA SI DE CERCETARE

- Coordonator în peste 20 de proiecte și granturi de cercetare naționale și internaționale
- Autor a 50 de articole publicate în jurnale indexate ISI
- Autor în 19 cărți/tratate/monografii
- Investigator principal în peste 25 de trialuri clinice
- Autor în peste 200 de lucrări prezentate la Conferințe și Congrese de specialitate
- 14 premii și distincții naționale și internaționale pentru activitatea profesională
- Consilier extern pe proiecte din programul cadru H2020 și proiecte naționale

PREMII, DISTINCTII

1. **Ordinul „Meritul Sanitar” în grad de Cavaler** oferit de Președintele României – decembrie 2019.

2. **Premiul „Carol Davila” pentru Medicină** – iunie 2019, Ateneul Român, București, MLNR în parteneriat cu Academia Română

3. **Premiul II pentru cercetare fundamentală, cel mai bun poster**, cu lucrarea - Transarterial embolization of hemorrhagic complications after percutaneous nephrolithotomy. B.S. Sandu, V. Jinga, **S. Rascu**, D. Badescu, S. Nedelea, D. Radavoi. European Urology Supplements, Volume 18, Issue 2, e2392, EAU 19th Central European Meeting, Vienna, Austria, 2019

4. **Premiul I pentru cercetare fundamentală, cel mai bun poster**, cu lucrarea - Genomic aspects regarding prostate cancer aggressiveness. Codreanu O., Cheorpeaca B., Radavoi D., Petca R, Jinga V., Badescu D. EAU 16th Central European Meeting, Vienna, Austria, 2016.

5. **Premiul I pentru cercetare fundamentala, cel mai bun poster**, cu lucrarea - Genetic studies on Romanian prostate cancer patients confirm genetic risk variants for prostate cancer. S. Rascu, V. Jinga, M. Dumitrache, M. Merticariu, R. Petca, D. Radavoi, D. Badescu. CEM 2014, 10-12 Octombrie, Cracovia, Polonia. ISSN: 1569-9056
6. **Premiul II pentru cercetare fundamentala, cel mai bun poster**, cu lucrarea - Percutaneous nephrolithotomy characteristics in elderly patients. Nedelea S., Borcaias R., Dragomiresteanu I., Petca R., Badescu D., Jinga V. Eur. Urol. Suppl 2013;12; e1242
7. **Diploma pentru cel mai bun recruiter** in studiul clinic: "Propiverine hydrochloride immediate and extended release: Comparison of efficacy and tolerability in patients with overactive bladder".
8. **Premiul Congresului Universitatii de Medicina si Farmacie "Carol Davila"**, Iunie 2013
9. **Premierea Rezultatelor Cercetării 2011**, lista 6, nr.crt: 1187. Articol premiat de CNCIS - *Occupational exposure to arsenic, cadmium, chromium, lead and nickel, and renal cell carcinoma: a case-control study from Central and Eastern Europe*. Revista **Occup Environ Med.** 2011 Oct;68(10):723-8. doi: 10.1136/oem.2010.056341. Epub 2011 Jan 8.
10. **"Premierea Rezultatelor Cercetării 2012**, lista 6, nr.crt: 1086. Articol premiat de CNCIS - *A germline variant in the TP53 polyadenylation signal confers cancer susceptibility*. Revista **Nat Genet.** 2011 Sep 25;43(11):1098-103. doi: 10.1038/ng.926.
11. **Premiul al III-lea, sesiunea de postere** pentru lucrarea: "Tumorile prostatei la pacientii cu sindrom metabolic", Rusu F., Rusu E., Radulian G., Enache G., Jinga M., Jinga V., Mischianu D., Cheta D.M., Societatea Romana de Diabet, Nutritie si Boli Metabolice, mai 2011.
12. **Premiul pentru cel mai bun poster** pentru lucrarea „Adipocitokinele si cancerul de prostata”; Rusu F., Rusu E., Dragomir A.D., Radulian G., Jinga V., Mischianu D., Cheta D.M., Societatea de Diabet, Nutritie si Boli Metabolice, mai 2010.
13. **Diploma Salonului de Carte Universitara** pentru lucrarea "Urologie pentru studenti" prezentata la cel de al III-lea Salon National de Carte Universitara desfasurat in Bucuresti in perioada 1-6 Octombrie 2007.
14. **Diploma Societatii Romane de Ultrasonografie in Medicina si Biologie** pentru lucrarea: "Uretrotomie interna optica ghidata ecografic transrectal pentru strictura bulbara proximala obliterated", Iunie 1998.

ANEXE

Lista de publicatii si lucrari stiintifice

Granturi/Proiecte de cercetare/dezvoltare – director/responsabil (cele mai reprezentative):

1. Titlul proiectului: **Deep-Learning and HPC to Boost Biomedical Applications for Health**

Acronimul proiectului: DeepHealth

Tip proiect: H2020

Responsabil proiect din partea Sp. Cl. Prof. Dr. Th. Burghele

Valoare contract: 12.800.000 Euro

2. Titlul proiectului: **Epidemiologia genetica a cancerului in Romania.**

Acronimul proiectului: RomCan

Tip proiect: International - Programul „Cercetare în Sectoare Prioritare”

Director proiect: Viorel Jinga

Valoare contract: 1.123.000 Euro

3. Titlul proiectului: ***Genetic prostate cancer variants as biomarkers of disease progression.***

Acronimul proiectului: ProMark

Contract nr. HEALTH-F2-2007-202059/2008, programul european FP7, 2008-2013

Coordonator: deCODE Genetics (Islanda)

Director proiect: dr. Thorunn Rafnar

Rol în proiect: responsabil de proiect din partea UMF “Carol Davila”

Valoare contract: 2 709 577 Euro

4. Titlul proiectului: ***Kidney cancer and occupational risk factors in Central and Eastern Europe***

Contract nr. ECE/00/06, finanțat de International Agency for Research on Cancer, IARC, Lyon, Franța și National Cancer Institute, USA, 2000-2004.

Coordonator: International Agency for Research on Cancer, IARC, Lyon, Franța

Director proiect: dr. Paul Brennan

Rol în proiect: responsabil proiect pentru UMF Carol Davila

Valoare contract: 19 200 USD

5. Titlul proiectului: **Global Renal Mass Study**

Coordonator: Clinical Research Office of the Endourological Society (CROES)

Perioada desfasurare: 2010-2011.

Rol în proiect: responsabil din partea Spitalului „Prof. Dr. Th. Burghel” (partener in proiect)

6. Titlul proiectului: **The Global URS Study**

Coordonator: Clinical Research Office of the Endourological Society (CROES)

Perioada desfasurare: 2010-2011.

Rol în proiect: responsabil din partea Spitalului „Prof. Dr. Th. Burghel” (partener in proiect)

7. Titlul proiectului: **“Workshop cu sesiuni practice în prostatectomia radicală robotică”**

Desfășurat în cadrul Spitalului Clinic “Prof. Dr. Th. Burghel” Bucuresti, 18-19 Noiembrie 2011

Codul CNCSIS al manifestării a fost PN-II-IDWE-2011-027.

Buget: 30.000 lei

Director proiect

8. Titlul proiectului: ***Optimizarea diagnosticului precoce in adenocarcinomul prostatic la pacienti cu sindrom metabolic prin corelarea factorilor genetici, anatomopatologici si biochimici.***

- Acronimul proiectului : ADENODIAG

- Perioada derularii: 18/09/2007 - 18/09/2010

- Valoarea totala a proiectului: 1.995.700 lei

- Directorul de proiect: Conf. Dr. Mischianu Dan Liviu Dorel

- Responsabil din partea Clinicii de Urologie “Prof. Dr. Th. Burghel” (partener in proiect)

9. Titlul proiectului: ***Markerii moleculari - Baza comuna de screening in tumorile epiteliale maligne***

- Perioada derularii: 2008 - 2011

- Valoarea proiectului: 458.066 lei

- Parteneri:

- Spitalul Clinic “Sf. Ioan”, Bucuresti (SCSI)
- Spitalul Universitar de Urgenta, Bucuresti (SUUB)
- Spitalul Clinic “Coltea”, Bucuresti (SCC)
- Spitalul Clinic “Theodor Burghel”, Bucuresti (SCTB) –

- Spitalul Clinic de Urgenta Floreasca, Bucuresti (SCUB)
 - Academia Oamenilor de Stiinta din Romania (AOSR)
- Director proiect: Dr Valeria Tica
- Responsabil din partea Clinicii de Urologie “Prof. Dr. Th. Burghel” (partener in proiect)

Articole ISI (cele mai reprezentative):

- A NEW ERA FOR THE THERAPEUTIC MANAGEMENT OF THE ONGOING COVID-19 PANDEMIC. Arsene AL, Dumitrescu IB, Dragoi CM, Udeanu DI, Lupuliasa D, **Jinga V**, Draganescu D, Dinu-Pirvu CE, Dragomiroiu GTAB, Blejan IE, Moisi RE, Nicolae AC, Moldovan H, Popa DE, Velescu BS, Ruta S. FARMACIA 2020 68(2): 185-196, DOI: 10.31925/farmacia.2020.2.1
- Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma. Stanciu AE, Zamfir-Chiru-Anton A, Stanciu M, Stoian AP, **Jinga V**, Nitipir C, Bucur A, Pituru TS, Arsene AL, Dragoi CM, Hainarosie R, Nicolae AC, Gherghe M, Gheorghe DC, Spandidos DA, Tsatsakis A, Papasavva M, Drakoulis N. ONCOLOGY LETTERS 2020 19(2): 1537-1543, DOI: 10.3892/ol.2019.11215
- A Short Overview of Recent Developments on Antimicrobial Coatings Based on Phytosynthesized Metal Nanoparticles. Fierascu I, Fierascu IC, Dinu-Pirvu CE, Fierascu RC, Anuta V, Velescu BS, Jinga M, **Jinga V**. COATINGS 2019 9(12): 787, DOI: 10.3390/coatings9120787
- Could Chemical Composition of Stone Influence Percutaneous Nephrolithotomy in the Management of Staghorn Calculi? Petca RC, Salaheddin Y, Petca A, Popescu RI, Mehedintu C, Maru N, **Jinga V**. REVISTA DE CHIMIE 2019 70(11): 3872-3877.
- Improved methodology of using simulators develops better practical skills in laparoscopy of future residents. Toma CV, Sima CS, Radavoi DG, Constantin T, Badescu DL, **Jinga V**. ROMANIAN JOURNAL OF MILITARY MEDICINE 2019 122(2):12-15.
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, **Jinga V**, Siefker-Radtke AO; BLC2001 Study Group. N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
- Sex specific associations in genome wide association analysis of renal cell carcinoma. Laskar RS, Muller DC, Li P, Machiela MJ, Ye Y, Gaborieau V, Foll M, Hofmann JN, Colli L, Sampson JN, Wang Z, Bacq-Daian D, Boland A, Abedi-Ardekani B, Durand G, Le Calvez-Kelm F, Robinot N, Blanche H, Prokhortchouk E, Skryabin KG, Burdett L, Yeager M, Radojevic-Skodric S, Savic S, Foretova L, Holcatova I, Janout V, Mates D, Rascu S, Mukeria A, Zaridze D, Bencko V, Cybulski C, Fabianova E, **Jinga V**, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Świątkowska B, Benhamou S, Cancel-Tassin G, Cussenot O, Trichopoulou A, Riboli E, Overvad K, Panico S, Ljungberg B, Sitaram RT, Giles GG, Milne RL, Severi

G, Bruinsma F, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Beane Freeman LE, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Chow WH, Moore LE, Choueiri TK, Wood C, Johansson M, McKay JD, Brown KM, Rothman N, Lathrop MG, Deleuze JF, Wu X, Brennan P, Chanock SJ, Purdue MP, Scelo G. *Eur J Hum Genet.* 2019 Jun 23. doi: 10.1038/s41431-019-0455-9. (Factor de impact: 3,65). PMID: 31231134

- Genetic Risk Score for Prostate Cancer in the Romanian Population. RAZVAN DANAU, DUMITRU CRISTINEL BADIU, PAUL IORDACHE, RADU URSU, VIORICA RADOI, STEFAN RASCU, GEORGE DANIEL RADAVOI, CRISTIAN SORIN SIMA, CRISTIAN TOMA, BOGDAN BRATICEVICI, MIHAELA MANDU, TITUS VALENTIN GRIGOREAN, **VIOREL JINGA**. *Rom Biotechnol Lett.* 2019; 24(1): 100-107. doi: 10.25083/rbl/24.1/100.107

- The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. Johansson M, Carreras-Torres R, Scelo G, Purdue MP, Mariosa D, Muller DC, Timpson NJ, Haycock PC, Brown KM, Wang Z, Ye Y, Hofmann JN, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Garnier JG, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Radojevic-Skodric S, Ognjanovic S, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, **Jinga V**, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Benhamou S, Cancel-Tassin G, Cussenot O, Weiderpass E, Ljungberg B, Tumkur Sitaram R, Häggström C, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Andreotti G, Beane Freeman LE, Koutros S, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Wilson KM, Gaziano JM, Sesso HD, Freedman ND, Parker AS, Eckel-Passow JE, Huang WY, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Lathrop GM, Deleuze JF, Gunter M, McKay JD, Wu X, Houlston RS, Chanock SJ, Relton C, Richards JB, Martin RM, Davey Smith G, Brennan P. *PLoS Med.* 2019 Jan 3;16(1):e1002724. doi: 10.1371/journal.pmed.1002724. eCollection 2019 Jan

- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, **Jinga V**, McCarthy S, Chowdhury S; TITAN Investigators. *N Engl J Med.* 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31

- OBESITY: A DELICATE ISSUE CHOOSING THE ESWL TREATMENT FOR PATIENTS WITH KIDNEY AND URETERAL STONES? Pricop C, Radavoi GD, Puia D, Vechiu C, **Jinga V**. *Acta Endocrinol (Buchar).* 2019 Jan-Mar;-5(1):133-138. doi: 10.4183/aeb.2019.133.

- Once-Daily Plazomicin for Complicated Urinary Tract Infections. Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, **Jinga V**, Dwyer JP; EPIC Study Group. N Engl J Med. 2019 Feb 21;380(8):729-740. doi: 10.1056/NEJMoa1801467
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, **Jinga V**, Smith MR; ARAMIS Investigators. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14
- Occupational exposure to urinary bladder carcinogens - risk factors, molecular mechanisms and biomarkers. Marina Ruxandra Otelea, **Viorel Jinga**, Alexandru Stefan Catalin Rascu, Iancu Emil Plesea, Amelia Nicoleta Petrescu, Luminita Elena Mitache, Mihai Olteanu, Dan Bondari, Agripina Rascu. Rom J Morphol Embryol 2018, 59(4)
- Phytochemical Profile and Biological Activities of *Satureja hortensis* L.: A Review of the Last Decade. Fierascu I, Dinu-Pirvu CE, Fierascu RC, Velescu BS, Anuta V, Ortan A, **Jinga V**. Molecules. 2018 Sep 25;23(10). pii: E2458. doi: 10.3390/molecules23102458. FACTOR IMPACT – 3,09
- Identification of Lynch syndrome risk variants in the Romanian population. Iordache PD, Mates D, Gunnarsson B, Eggertsson HP, Sulem P, Benonisdottir S, Csiki IE, Rascu S, Radavoi D, Ursu R, Staicu C, Calota V, Voinoiu A, Jinga M, Rosoga G, Danau R, Sima SC, Badescu D, Suciu N, Radoi V, Mates IN, Dobra M, Nicolae C, Kristjansdottir S, Jonasson JG, Manolescu A, Arnadottir G, Jensson B, Jonasdottir A, Sigurdsson A, le Roux L, Johannsdottir H, Rafnar T, Halldorsson BV, **Jinga V**, Stefansson K. J Cell Mol Med. 2018 Dec;22(12):6068-6076. doi: 10.1111/jcmm.13881. Epub 2018 Oct 16.
- Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, Arranz Arijia JA, Shih KC, Radavoi GD, Xu N, Chan WY, Ma H, Gendreau S, Riisnaes R, Patel PH, Maslyar DJ, **Jinga V**. Clin Cancer Res. 2018 Jul 23. doi: 10.1158/1078-0432.CCR-18-0981.
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, **Jinga V**, Small EJ. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8
- Profile of common prostate cancer risk variants in an unscreened Romanian population. Iordache PD, Mates D, Gunnarsson B, Eggertsson HP, Sulem P, Guðmundsson J, Benónisdóttir S, Csiki IE, Rascu S, Radavoi D, Ursu R, Staicu C, Calota V, Voinoiu A, Jinga M, Rosoga G, Danau R, Sima SC, Badescu D, Suciu N, Radoi V, Manolescu A, Rafnar T, Halldórsson BV, **Jinga V**, Stefánsson K. J Cell Mol Med. 2018 Mar;22(3):1574-1582. doi: 10.1111/jcmm.13433. Epub 2017 Dec 20.
- Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. Machiela MJ, Hofmann JN, Carreras-Torres R, Brown KM, Johansson M, Wang Z, Foll M, Li P, Rothman N, Savage

SA, Gaborieau V, McKay JD, Ye Y, Henrion M, Bruinsma F, Jordan S, Severi G, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Mannisto S, Weinstein S, Clark PE, Edwards TE, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Gaziano JM, Sesso HS, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Colli LM, Sampson JN, Besse C, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Mijuskovic M, Ognjanovic M, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jina V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Bueno-de-Mesquita HB, Canzian F, Duell EJ, Ljungberg B, Sitaram RT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Larkin J, Choueiri TK, Lathrop GM, Teh BT, Deleuze JF, Wu X, Houlston RS, Brennan P, Chanock SJ, Scelo G, Purdue MP. *Eur Urol.* 2017 Nov;72(5):747-754. doi: 10.1016/j.eururo.2017.07.015. Epub 2017 Aug 7. Erratum in: *Eur Urol.* 2018 May 28;:. PMID: 28797570 Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Scelo G, Purdue MP, Brown KM, Johansson M, Wang Z, Eckel-Passow JE, Ye Y, Hofmann JN, Choi J, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Sampson JN, Abedi-Ardekani B, Besse C, Blanche H, Boland A, Burdette L, Chabrier A, Durand G, Le Calvez-Kelm F, Prokhortchouk E, Robinot N, Skryabin KG, Wozniak MB, Yeager M, Basta-Jovanovic G, Dzamic Z, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, **Jinga V**, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Baglietto L, Boeing H, Khaw KT, Weiderpass E, Ljungberg B, Sitaram RT, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Mark Lathrop G, Rothman N, Deleuze JF, McKay JD, Parker AS, Wu X, Houlston RS, Brennan P, Chanock SJ. *Nat Commun.* 2017 Jun 9;8:15724. doi: 10.1038/ncomms15724

- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S1, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN, Korbenfeld E, Metrebian S, Kaen L, Staneloni E, Batagelj E, Tan H, Hovey E, Woo H, Frydenberg M, Chua W, D'Hondt L, Evaraert E, Verschaeve V, Wynendaele W, Schrijvers D, Waltregny D, Whenham N, Demey W, Franke F, Panhoca R, Damião R, Zucca L, Da Rosa V, Reis R, Scalabrini A, Nahas W, Girotto G, Nogueira A, Gomes A, Coradazzi A, Kurteva G, Siemens R, Gingerich J, Fleshner N, Fradet Y, Morgan S, North S, Saad F, Shayegan B, Zalewski P, Pinochet R, Orellana N, Ding Q, Ye Z, Xie L, Du C, Chen Z, Huang Y, Sun Z, Li H, Jin J, Li C, Wan B, Tian Y, Zhou F, Xie K, Yao X, Qiu M, Zou Q, Na Y, Sun Y, Xue B, Ma L, Martinez C, Salazar M, Larios C, Solano S, Pavlik I, Brodak M, Hora M, Büchler T, Borre M, Johansen J, Mejlholm I, Poulsen M, Wittendorf HE, Tammela T, Vaarala M, Theodore C, Staudacher L, Villers A, Laplaige P, Suttman H, Steuber T, Natale S, Jones R, Tran A, Mazhar D, Mills J, Nyirady P, Salamon C, Torzsok F, Feher

J, Géczi L, Lakatos A, Keizman D, Sella A, Frank S, Peer A, Rosenbaum E, Berger R, Mermershtain W, Carteni G, Tonini G, De Giorgi U, Facchini G, Berruti A, Bracarda S, Basso U, Galli L, Tortora G, Alietta M, Fukasawa S, Suzuki H, Hasumi H, Tsuchiya T, Uemura H, Kanayama H, Hashine K, Sato F, Matsumoto H, Oya M, Lee JL, Park S, Keam B, Yun H, Kim Y, Kang B, Lee K, Kim C, Saad M, Sundram M, Calvo D, Moreno R, Rodriguez J, Hernandez C, van den Berg H, De La Rosett J, Van Moorse R, Hunting J, Hendriks M, Kueppers F, Gilling P, Beaven A, Holmes M, Jassem J, Oszukowska E, Niezabitowski J, Jaxa-Larecka D, Chwalinski M, Swiniarski P, Silva C, Conceição P, Fraga A, Mauricio J, Rodrigues T, Pinheiro L, Lima E, Palma Dos Reis J, Volovat C, **Jinga V**, Harza M, Alyasova A, Budnik N, Bychkov Y, Izmaylov A, Khvorosten D, Matveev V, Novsov A, Vladimirov V, Tevs D, Sheveleva L, Bulanov A, Semenov A, Fadeeva N, Kulikov E, Emelyanov S, Karyakin O, Shirinkin V, Shkolnik M, Lykov A, Skopin P, Kopyltsov E, Mincik I, Mir O, Kliment J, Mikurcik E, Gajdos M, Milichovsky I, Malan J, Bahlmann J, Moshokoa E, Madlala T, Coetzee L, Ribal M, Miñana B, Martinez Breijo S, Carballido J, Olmos D, Requena M, Morote J, Damber JE, Haggman M, Nyman C, Ljungberg B, Bjartell A, Ozen H, Beduk Y, Sozen S, Cetinkaya M, Ozyurt M, Tansug Z, Mungan A, Tanidir Y, Toktas M, Hotko E, Stus V, Lyulko O, Vinnyk Y, Shparyk Y, Sakalo V, Bondarenko I, Paramonov V, Khareba G, Hodos V. *N Engl J Med* 2017;377(4):352-360.

- Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma. Arseneault M, Monlong J, Vasudev NS, Laskar RS, Safisamghabadi M, Harnden P, Egevad L, Nourbehesht N, Panichnantakul P, Holcatova I, Brisuda A, Janout V, Kollarova H, Foretova L, Navratilova M, Mates D, **Jinga V**, Zaridze D, Mukeria A, Jandaghi P, Brennan P, Brazma A, Tost J, Scelo G, Banks RE, Lathrop M, Bourque G, Riazalhosseini Y. *Sci Rep* 2017; ;7:44876. doi: 10.1038/srep44876.
- Replication study of 34 common SNPs associated with prostate cancer in the Romanian population. **Viorel Jinga**, Irma Eva Csiki, Andrei Manolescu, Paul Iordache, Ioan Nicolae Mates, Daniel Radavoi, Stefan Rascu, Daniel Badescu, Paula Badea, Dana Mates. *Journal of Cellular and Molecular Medicine* 2016, ISSN: 1582-4934, <http://onlinelibrary.wiley.com/doi/10.1111/jcmm.12729/epdf>
- A comprehensive analysis of genome-wide association studies to identify prostate cancer susceptibility loci for the Romanian population. Rădăvoi GD, Pricop C, **Jinga V**, Mateş D, Rădoi VE, Jinga M, Ursu RI, Bratu OG, Mischianu DL, Iordache P. *Rom J Morphol Embryol.* 2016;57(2):467-75
- Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer. Stacey SN, Kehr B, Gudmundsson J, Zink F, Jonasdottir A, Gudjonsson SA, Sigurdsson A, Halldorsson BV, Agnarsson BA, Benediktsdottir KR, Aben KK, Vermeulen SH, Cremers RG, Panadero A, Helfand BT, Cooper PR, Donovan JL, Hamdy FC, **Jinga V**, Okamoto I, Jonasson JG, Tryggvadottir L, Johannsdottir H, Kristinsdottir AM, Masson G, Magnusson OT, Iordache PD, Helgason A, Helgason H, Sulem P, Gudbjartsson DF, Kong A, Jonsson E, Barkardottir RB, Einarsson GV, Rafnar T, Thorsteinsdottir U, Mates IN, Neal DE, Catalona WJ, Mayordomo JI, Kiemeny LA, Thorleifsson G, Stefansson K. *Hum Mol Genet.* 2016 Mar 1;25(5):1008-18. doi: 10.1093/hmg/ddv622. Epub 2016 Jan 5

- Aristolochic acid exposure in Romania and implications for renal cell carcinoma. Turesky RJ, Yun BH, Brennan P, Mates D, **Jinga V**, Harnden P, Banks RE, Blanche H, Bihoreau MT, Chopard P, Letourneau L, Lathrop GM, Scelo G. Br J Cancer. 2016 Jan 12;114(1):76-80. doi:10.1038/bjc.2015.402.
- Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer. Le Bret T, Rouanne M, Hublarov O, **Jinga V**, Petkova L, Kotsev R, Sinescu I, Dutailly P. Therapeutic Advances in Urology 2015. ISSN: 1756-2872
- Orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Saad F, Fizazi K, **Jinga V**, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigator. The Lancet Oncology 2015. ISSN: 1470-2045
- Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, González-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanché H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, **Jinga V**, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM. Nat Commun. 2014 Oct 29;5:5135. doi: 10.1038/ncomms6135 ISSN: 2041-1723
- Differences in Ureteroscopic Stone Treatment and Outcomes for Distal, Mid-, Proximal, or Multiple Ureteral Locations: The Clinical Research Office of the Endourological Society Ureteroscopy Global Study. Perez Castro E, Osther PJ, **Jinga V**, Razvi H, Stravodimos KG, Parikh K, Kural AR, de la Rosette JJ; on behalf of the CROES Ureteroscopy Global Study Group. Eur Urol. 2014 Jan 23. pii: S0302-2838(14)00023-2. ISSN: 0302-2838
- Transarterial embolization of renal vascular lesions after percutaneous nephrolithotomy. **Jinga V**, Dorobat B, Youssef S, Radavoi G, Braticevici B, Filipoiu F, Balgradean M. Chirurgia (Bucur). 2013 Jul-Aug;108(4):521-9. ISSN: 1221-9118
- Gentamicin, infections, and acute tubular necrosis in children. M. Bălgrădean, E. Cintează, F. Filipoiu, **V. Jinga**. Farmacia 2013;61:772-80. ISSN: 0014-8237
- Sudden death of a premature newborn with hypoplastic left heart syndrome. Morphological study of the heart. Filipoiu F.M., Bălgrădean M., **Jinga V**. Romanian Journal of Legal Medicine 2013; 21:27-30. ISSN: 1221-8618
- Anatomical description of the deep venous channel from the anterior vestibular wall of the right atrium. Filipoiu F.M., Balgradean M., Brezean I., **Jinga V**. Rom J Morphol Embryol. 2013;54(3). ISSN: 1220-0522
- Risk factors and complications leading to mortality from hemolytic uremic syndrome in child. Three case reports. Balgradean M., Cinteza E., Filipoiu F., **Jinga V**. RJLM 2013; XXI. ISSN: 1221-8618

- Ventral buccal mucosa graft urethroplasty for penile urethral strictures: a predictable failure? **Jinga V**, Hurduc M, Voinescu V, Filipoiu F, Balgradeanu M. Chirurgia (Bucur). 2013 Mar-Apr;108(2):245-9. ISSN: 1221-9118
- Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity. Stöhrer M, Mürtz G, Kramer G, Warnack W, Primus G, **Jinga V**, Manu-Marin A, Calomfirescu N, Strugala G. Spinal Cord. 2013 May;51(5):419-23. doi: 10.1038/sc.2012.174. Epub 2013 Jan 22. ISSN: 1362-4393
- Death caused by hemolytic-uremic syndrome. Case series. Balgradeanu M., Ceausu M., Cinteza E., Filipoiu F., Hostiuc S., **Jinga V**, Sirbu D., Spataru R.I. RJLM 2013; XXI
- A rare case of digestive hemorrhage in an elderly patient: diagnosis and treatment difficulties. Jinga M, Jurcuț C, Vasilescu F, Becheanu G, Stancu SH, Ciobaca L, Mircescu G, **Jinga V**. Rom J Morphol Embryol. 2012;53(3 Suppl):831-4. ISSN: 1220-0522
- Penile abscess and urethrocutaneous fistula following intracavernous injection: a case report. **Jinga V**, Iconaru V. J Sex Med. 2012 Dec;9(12):3270-3. doi: 10.1111/j.1743-6109.2012.02959.x. Epub 2012 Oct 22. ISSN: 1743-6095
- Single nucleotide polymorphisms in colorectal cancer: associations with tumor site and TNM stage. Mates IN, **Jinga V**, Csiki IE, Mates D, Dinu D, Constantin A, Jinga M. J Gastrointest Liver Dis. 2012 Mar;21(1):45-52. ISSN: 1841-8724
- A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Agnarsson BA, Benediksdottir KR, Sigurdsson A, Magnusson OT, Gudjonsson SA, Magnusdottir DN, Johannsdottir H, Helgadottir HT, Stacey SN, Jonasdottir A, Olafsdottir SB, Thorleifsson G, Jonasson JG, Tryggvadottir L, Navarrete S, Fuertes F, Helfand BT, Hu Q, Csiki IE, Mates IN, **Jinga V**, Aben KK, van Oort IM, Vermeulen SH, Donovan JL, Hamdy FC, Ng CF, Chiu PK, Lau KM, Ng MC, Gulcher JR, Kong A, Catalona WJ, Mayordomo JI, Einarsson GV, Barkardottir RB, Jonsson E, Mates D, Neal DE, Kiemenev LA, Thorsteinsdottir U, Rafnar T, Stefansson K. Nat Genet. 2012 Dec;44(12):1326-9. doi: 10.1038/ng.2437. Epub 2012 Oct 28. ISSN: 1061-4036
- A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, Prokhortchouk E, Gaborieau V, Jacobs KB, Chow WH, Toro JR, Zaridze D, Lin J, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, **Jinga V**, Bencko V, Slamova A, Holcatova I, Navratilova M, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL 3rd, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Virtamo J, Vatten L, Hveem K, Fletcher T, Koppova K, Cussenot O, Cancel-Tassin G, Benhamou S, Hildebrandt MA, Pu X, Foglio M, Lechner D, Hutchinson A, Yeager M, Fraumeni JF Jr, Lathrop M, Skryabin KG, McKay JD, Gu J, Brennan P, Chanock SJ. Hum Mol Genet. 2012 Jan 15;21(2):456-62. doi: 10.1093/hmg/ddr479. Epub 2011 Oct 18. ISSN: 0964-6906

- A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Nexø BA, Tjønneland A, Overvad K, Rudnai P, Gurzau E, Koppova K, Hemminki K, Corredera C, Fuentelsaz V, Grasa P, Navarrete S, Fuertes F, García-Prats MD, Sanambrosio E, Panadero A, Juan AD, Garcia A, Rivera F, Planelles D, Soriano V, Requena C, Aben KK, Rossum MM, Cremers RG, Oort IM, van Spronsen DJ, Schalken JA, Peters WH, Helfand BT, Donovan JL, Hamdy FC, Badescu D, Codreanu O, Jinga M, Csiki IE, Constantinescu V, Badea P, Mates IN, Dinu DE, Constantin A, Mates D, Kristjansdottir S, Agnarsson BA, Jonsson E, Barkardottir RB, Einarsson GV, Sigurdsson F, Moller PH, Stefansson T, Valdimarsson T, Johannsson OT, Sigurdsson H, Jonsson T, Jonasson JG, Tryggvadottir L, Rice T, Hansen HM, Xiao Y, Lachance DH, O'Neill BP, Kosel ML, Decker PA, Thorleifsson G, Johannsdottir H, Helgadottir HT, Sigurdsson A, Steinhorsdottir V, Lindblom A; Swedish Low-risk Colorectal Cancer Study Group, Sandler RS, Keku TO, Banasik K, Jørgensen T, Witte DR, Hansen T, Pedersen O, **Jinga V**, Neal DE, Catalona WJ, Wrensch M, Wiencke J, Jenkins RB, Nagore E, Vogel U, Kiemeny LA, Kumar R, Mayordomo JI, Olafsson JH, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K. Nat Genet. 2011 Sep 25;43(11):1098-103. doi: 10.1038/ng.926. ISSN: 1061-4036
- Correlation between albuminemia, natremia and survival rates in patients with hepatorenal syndrome. Niculae A, Jinga M, Ciocâlțeu A, Lascăr I, **Jinga V**, Checheriță IA. Rom J Morphol Embryol. 2011;52(3):863-6. ISSN: 1220-0522
- Occupational exposure to arsenic, cadmium, chromium, lead and nickel, and renal cell carcinoma: a case-control study from Central and Eastern Europe. Boffetta P, Fontana L, Stewart P, Zaridze D, Szeszenia-Dabrowska N, Janout V, Bencko V, Foretova L, **Jinga V**, Matveev V, Kollarova H, Ferro G, Chow WH, Rothman N, van Bemmelen D, Karami S, Brennan P, Moore LE. Occup Environ Med. 2011 Oct;68(10):723-8. ISSN: 1351-0711
- Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, **Jinga V**, Fernández Fernández E; European Silodosin Study Group. Eur Urol. 2011 Mar;59(3):342-52.
- Screening for Prostatic Tumors in Metabolic Syndrome Patients in Romania. Rusu F, Rusu E, Radulian G, Enache G, Jinga M, Rusu A, **Jinga V**, Codreanu O, Mischianu D, Cheta D. Acta Endo (Buc) 2011 (7): 47-58.
- Genetic correction of PSA values using sequence variants associated with PSA levels. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, Agnarsson BA, Benediktsdottir KR, Isaksson HJ, Kostic JP, Gudjonsson SA, Stacey SN, Gylfason A, Sigurdsson A, Holm H, Bjornsdottir US, Eyjolfsson GI, Navarrete S, Fuertes F, Garcia-Prats MD, Polo E, Checherita IA, Jinga M, Badea P, Aben KK, Schalken JA, van Oort IM, Sweep FC, Helfand BT, Davis M, Donovan JL, Hamdy FC, Kristjansson K, Gulcher JR, Masson G, Kong A, Catalona WJ, Mayordomo JI, Geirsson G, Einarsson GV, Barkardottir RB, Jonsson E, **Jinga V**, Mates D, Kiemeny LA, Neal DE, Thorsteinsdottir U, Rafnar T, Stefansson K. Sci Transl Med. 2010 Dec 15;2(62):62ra92. doi: 10.1126/scitranslmed.3001513.

Studii clinice internationale – investigator principal:

1. Studiu de faza III : "AV-951-09-301, A phase 3, randomized, controlled, multi-center, open label study to compare Tivozanib (AV-951) to Sorafenib in subjects with advanced renal cell carcinoma ", inceput in Ianuarie 2010 si aflat in desfasurare in cadrul Sectiei III Urologie - Spitalul Clinic "Prof. Dr. Th. Burghele".
2. Studiu de faza III : "AV-951-09-902, An Extension Treatment Protocol for Subjects who have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma", inceput in martie 2010 si aflat in desfasurare in cadrul Sectiei III Urologie - Spitalul Clinic "Prof. Dr. Th. Burghele".
3. Studiu de faza II/III: AN International, Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate whether Trovax, Added to First Line Standard of Care Therapy, Prolongs the Survival of Patients WITH Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma" inceput in Oct. 2006 si incheiat in Apr. 2010, studiu desfasurat in cadrul Sectiei III Urologie-Spitalul Clinic "Prof. Dr.Th. Burghele".
4. Studiu de faza II/III: "A randomized, open-label, multi-centre, phase II/III study on treatment with ABR-217620 combined with INF- α vs. INF- α alone in patients with advanced renal cell carcinoma", inceput in Febr. 2007 si aflat in desfasurare in cadrul Sectiei III Urologie -Spitalul Clinic "Prof. Dr. Th. Burghele".
5. Studiu de faza 1b/2: "Study of Docetaxel and Prednisone, with or without ISIS 183750 (an eIF4E Inhibitor), in Patients with Castrate-Resistant Prostate Cancer", inceput in ianuarie 2011 si aflat in desfasurare in cadrul Sectiei III Urologie - Spitalul Clinic "Prof. Dr.Th. Burghele".
6. Studiu de faza III: "An open-label, multi-centre, extension study, evaluating the long-term safety and tolerability of study drug one-month dosing regimen in patients with prostate cancer requiring androgen ablation therapy", inceput in Mai 2007 si aflat in desfasurare in desfasurare in cadrul Sectiei III Urologie- Spitalul Clinic "Prof. Dr. Th. Burghele".
7. Studiu de faza III: "An open-label, multi-centre, randomised, parallel-arm one-year trial, comparing the efficacy and safety of study drug three-month dosing regimen with Goserelin Acetate in patients with prostate cancer requiring androgen deprivation therapy", desfasurat intre August 2009 si Martie 2011 in cadrul Sectiei III Urologie -Spitalul Clinic "Prof. Dr. Th. Burghele".
8. Studiu de faza III: "An open-label, multi-centre, randomised, parallel-group, dose-finding study, investigating efficacy and safety of two study drug three-month dosing regimens in patients with prostate cancer requiring androgen ablation therapy, desfasurat intre Iunie 2007 si August 2008, in cadrul Sectiei III Urologie -Spitalul Clinic "Prof. Dr. Th. Burghele".
9. Studiu de faza III, cu protocolul C21004: A Phase 3, Randomized, Double-Blind, Multicenter trial Comparing Orteronel Plus Prednisone with Placebo plus Prednisone in Patents with Chemotherapy - Naive Metastatic Castration-Resistant Prostate Cancer.
10. Studiu de faza III, cu protocolul C21005: A Phase 3, Randomized, Double-Blind, Multicenter trial Comparing Orteronel Plus Prednisone with Placebo plus Prednisone in Patents with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or following Docetaxel-based therapy.
11. Studiu de faza II cu protocolul C21012: A Phase 2, Open Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patents With Metastatic Castration- Resistant Prostate Cancer.

12. Un studiu de faza Ib/II cu protocolul GO27983: A Phase Ib/II Study of GDC-0068 or GDC-0980 with Abiraterone Acetate versus Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy.
13. Investigator principal in studiul Ferring Pharmaceuticals Inc. Study cu protocolul FE 200486 CS35A: Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy.
14. Investigator Principal in studiul AstraZeneca de faza III cu protocolul D4280C00004: A Phase III, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ 104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram-Negative Pathogen in Hospitalized Adults.
15. Investigator Principal in studiul AstraZeneca de faza III cu protocolul D4280C00006 : An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram-Negative Pathogens.
16. Investigator Principal in studiul clinic international D-20762-2003: "Efficacy and safety of repeated doses of cetrorelix pamoate in symptomatic patients with BPH" in 2002-2004 sponsore by Zentaris GmbH.
17. Investigator Principal in studiul clinic international 8401060: "Propiverine hydrochloride immediate release (IR) and extended release (ER): Comparison of efficacy and tolerability in patients with overactive bladder" in 2002-2003 sponsored by Apogepha Arzneimittel GmbH.
18. Investigator Principal in studiul clinic international 8405010: "Efficacy and tolerability of propiverine hydrochloride extended release (ER) compared to immediate release (IR) in patients with neurogenic detrusor overactivity" in 2005-2006 sponsored by Apogepha Arzneimittel GmbH.
19. Investigator Principal in studiul clinic international 8406031: "Dose-finding study of propiverine hydrochloride after intravesical administration of 15, 30 or 60 mg t.i.d. in patients with neurogenic detrusor overactivity" in 2006-2007 sponsored by Apogepha Arzneimittel GmbH.
20. Investigator Principal in studiul clinic international D-20761-2006: "Efficacy and safety of cetrorelix acetate in patients with AUR due to BPH" in 2002-2003 sponsored by Zentaris GmbH.
21. Investigator Principal in studiul clinic international AEZS-102-036: "Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study" in 2008-2010 sponsored by Aeterna Zentaris GmbH.
22. Investigator principal in studiul clinic international de faza III, KMD 3213 IT-CL 0215 desfasurat in Spitalul "Prof. Dr. Th. Burghele" in perioada 2006-2007.
23. Investigator principal in studiul clinic international, randomizat, dublu-orb, placebo-controlat ACTION 617-EC-008, desfasurat in Spitalul "Prof. Dr. Th. Burghele" in perioada 2005-2006.
24. Investigator principal in studiul de faza II cu protocolul 3652-CL-0018: A randomized, double-blind, placebo-controlled, parallel group, adaptive, combined Proof of Concept and dose-finding study to investigate efficacy, safety,

pharmacodynamics and pharmacokinetics of ASP 3652 in the treatment of female subjects with bladder pain syndrome/ interstitial cystitis.

25. Investigator principal in studiul de faza II cu protocolul 9785-CL-0222: A randomized, double-blind, phase II, efficacy and safety study of MDV3100 (ASP9785) vs. bicalutamide in castrate men with metastatic prostate cancer.

26. Investigator principal in studiul de faza III cu protocolul D4320C00033: A randomized, double-blind study to assess the efficacy and safety of 10 mg ZD4054 in combination with Docetaxel in comparison with Docetaxel in patients with metastatic hormone-resistant prostate cancer.

27. Investigator principal in studiul de faza III cu protocolul D4320C00015: A randomized, placebo-controlled, double-blind study to assess the efficacy and safety of once-daily orally administered ZD4054 10 mg in non-metastatic hormone –resistant prostate cancer patients.

04.05.2020

Prof. Univ. Dr.
Viorel JINGA